Quick Comparison
| Emoxypine (Mexidol) | Noopept | |
|---|---|---|
| Half-Life | 2-2.6 hours | 30-60 minutes (active metabolite cycloprolylglycine persists longer) |
| Typical Dosage | Standard: 125-375 mg daily in 2-3 divided doses. Commonly 125 mg twice daily. Take with food. Effects are noticeable within 30-60 minutes. Russian clinical practice uses 4-6 week courses. | Standard: 10-30 mg sublingually or orally, 2-3 times daily. Sublingual administration provides faster onset. Do not exceed 30 mg per dose. |
| Administration | Oral (tablets). Also available as IV/IM injection in clinical settings. Mexidol is the brand name. | Oral or sublingual (sublingual preferred for faster onset and higher bioavailability). Available as powder, capsules, or sublingual tablets. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
Emoxypine (Mexidol)
Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine succinate) has a 3-hydroxypyridine structure similar to vitamin B6 (pyridoxine). It is one of the most potent inhibitors of lipid peroxidation in brain tissue — it scavenges hydroxyl radicals and peroxyl radicals, inhibits Fe2+-induced lipid peroxidation, and may chelate transition metals. It modulates the GABA-benzodiazepine receptor complex (GABA-A), enhancing GABAergic transmission through positive allosteric modulation — possibly at a site distinct from the classical benzodiazepine binding site, explaining the lack of sedation and tolerance. It improves mitochondrial function (Complex I protection, membrane stabilization), stabilizes cell membranes (reducing fluidity changes during oxidative stress), and enhances cerebral microcirculation (possibly via nitric oxide or prostaglandin modulation). The anxiolytic mechanism may involve partial agonism or different subunit selectivity.
Noopept
Noopept modulates AMPA and NMDA receptors similarly to racetams through positive allosteric modulation. Its key distinguishing feature is upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) via activation of TrkB and TrkA receptor signaling cascades — these neurotrophins are essential for neuronal growth, survival, dendritic arborization, and synaptic plasticity. Noopept inhibits glutamate-induced excitotoxicity by reducing calcium influx through NMDA receptors and modulating the NR2B subunit. It activates the PI3K/Akt and MAPK/ERK pathways downstream of neurotrophin receptors. The active metabolite cycloprolylglycine (a cyclic dipeptide) has endogenous nootropic activity, potentially acting as a trace amine-associated receptor ligand. Neuroprotection is further mediated through antioxidant effects and mitochondrial stabilization.
Risks & Safety
Emoxypine (Mexidol)
Common
Mild nausea, drowsiness, dry mouth.
Serious
Limited Western safety data. Allergic reactions reported.
Rare
Elevated blood pressure, emotional lability.
Noopept
Common
Headache (especially without choline supplementation), irritability at higher doses, brain fog in some users.
Serious
No serious adverse effects documented.
Rare
Emotional blunting at high doses, insomnia, allergic reactions.
Full Profiles
Emoxypine (Mexidol) →
A vitamin B6 derivative with powerful antioxidant and anxiolytic properties, widely prescribed in Russia and Eastern Europe for anxiety, cognitive impairment, and cerebrovascular disease. Emoxypine inhibits lipid peroxidation, modulates GABA-A and benzodiazepine binding sites, and improves cerebral blood flow. It provides anxiolytic effects similar to benzodiazepines without sedation, tolerance, or addiction.
Noopept →
A synthetic peptide-derived nootropic often grouped with racetams due to similar effects, though it is technically a dipeptide analog of piracetam. Roughly 1000x more potent by weight than piracetam, requiring only 10-30 mg per dose. It provides both immediate cognitive enhancement and long-term neuroprotective benefits through BDNF and NGF upregulation.